Search research articles
Contact Us
Filters
Showing results (41-50 of 54) with videos related to
Page
of 6
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2007
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
R S Midgley, D J Kerr, K T Flaherty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2014
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma
A Gupta, S Love, A Schuh, et al.
British Journal of Cancer
|
February 18, 2011
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
O A Khan, M Gore, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 24, 2015
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
M R Middleton, P Friedlander, O Hamid, et al.
British Journal of Cancer
|
April 16, 2009
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
A J Watson, M R Middleton, G McGown, et al.
British Journal of Cancer
|
November 20, 1998
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma
M R Middleton, J M Lunn, C Morris, et al.
Targeted Oncology
|
May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J Mateo, V Moreno, A Gupta, et al.
British Journal of Cancer
|
March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
S P Blagden, L R Molife, A Seebaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
M R Middleton, J J Grob, N Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
D S Boss, G K Schwartz, M R Middleton, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 54) with videos related to
Sort By:
Page
of 6
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 12, 2007
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan
R S Midgley, D J Kerr, K T Flaherty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2014
DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma
A Gupta, S Love, A Schuh, et al.
British Journal of Cancer
|
February 18, 2011
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
O A Khan, M Gore, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 24, 2015
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
M R Middleton, P Friedlander, O Hamid, et al.
British Journal of Cancer
|
April 16, 2009
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib
A J Watson, M R Middleton, G McGown, et al.
British Journal of Cancer
|
November 20, 1998
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma
M R Middleton, J M Lunn, C Morris, et al.
Targeted Oncology
|
May 13, 2016
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J Mateo, V Moreno, A Gupta, et al.
British Journal of Cancer
|
March 6, 2008
A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
S P Blagden, L R Molife, A Seebaran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
M R Middleton, J J Grob, N Aaronson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 15, 2009
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
D S Boss, G K Schwartz, M R Middleton, et al.
Page
of 6